Search Results

A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) MOA: Giredestrant is an oral selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Locally advanced or metastatic…

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) MOA: Rinatabart sesutecan (Rina-S) is an FRα-directed antibody drug conjugate with an exatecan payload. Key Eligibility Criteria: Cohort B3 – EGFR-mutated NSCLC Must have received EGFR-targeted therapy and plt-based chemo Part C – High-grade serous PROC 1-3 prior lines…

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB) MOA: LY3537982 is…

Maryland Oncology’s Laurel location is located adjacent from the former Laurel Regional Hospital. MOH’s Laurel location was founded in 2011 with only one provider 2 days a week. MOH’s Laurel location is open 2 ½ days a week with 2 Oncologist serving the Oncology Hematology patients in the area.

Take A Virtual Tour